Humacyte (NASDAQ:HUMA) Stock Price Expected to Rise, Benchmark Analyst Says

Humacyte (NASDAQ:HUMA) had its target price upped by analysts at Benchmark from $15.00 to $17.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Benchmark’s price objective would indicate a potential upside of 276.94% from the stock’s previous close.

A number of other equities research analysts also recently issued reports on the stock. Piper Sandler set a $6.00 price objective on shares of Humacyte and gave the stock a “neutral” rating in a research report on Friday, October 18th. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 target price on shares of Humacyte in a report on Friday, December 20th. BTIG Research reiterated a “buy” rating and set a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. TD Cowen restated a “buy” rating and issued a $10.00 price objective on shares of Humacyte in a research note on Friday, October 18th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 target price on shares of Humacyte in a research note on Friday, September 20th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $13.71.

Humacyte Stock Performance

NASDAQ HUMA opened at $4.51 on Monday. The company has a fifty day moving average price of $4.81 and a 200-day moving average price of $5.81. The firm has a market cap of $567.62 million, a price-to-earnings ratio of -3.37 and a beta of 1.38. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 1.10. Humacyte has a 1 year low of $2.48 and a 1 year high of $9.97.

Insider Buying and Selling at Humacyte

In related news, Director Brady W. Dougan sold 427,459 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the sale, the director now directly owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. This represents a 17.67 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Laura E. Niklason sold 261,369 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total transaction of $1,150,023.60. Following the completion of the transaction, the chief executive officer now directly owns 1,730,884 shares of the company’s stock, valued at approximately $7,615,889.60. This trade represents a 13.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,500,000 shares of company stock valued at $6,606,799. Company insiders own 11.20% of the company’s stock.

Institutional Investors Weigh In On Humacyte

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. State Street Corp grew its position in shares of Humacyte by 66.1% in the third quarter. State Street Corp now owns 4,764,155 shares of the company’s stock valued at $25,917,000 after purchasing an additional 1,895,529 shares in the last quarter. Millennium Management LLC boosted its stake in Humacyte by 504.3% in the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after purchasing an additional 1,334,641 shares during the period. Renaissance Technologies LLC grew its holdings in Humacyte by 693.0% during the 2nd quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock valued at $2,881,000 after buying an additional 524,600 shares in the last quarter. Marshall Wace LLP increased its position in shares of Humacyte by 3,301.5% during the second quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock valued at $2,226,000 after buying an additional 450,031 shares during the period. Finally, Deerfield Management Company L.P. Series C purchased a new stake in shares of Humacyte in the second quarter worth about $1,550,000. Institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.